Trial reportFrontiers in endocrinology2026
Acute TRPTI™ (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study.
Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06840080 (Short-term Effect of Oleoylethanolamide), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Short-term Effect of Oleoylethanolamide (OEA) and LipiSperse Supplementation on Metabolic Pathways in Otherwise Healthy Participants - a Single Blind, Cross-over Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oleoylethanolamide (OEA) is an endogenous lipid mediator involved in nutrient sensing and gut-derived hormonal signalling. TRPTI™ is a bioavailable OEA formulation designed to support metabolic and appetite-related pathways. This study evaluated the acute metabolic effects of TRPTI™ in healthy adults under controlled feeding conditions. Methods: In this fixed-sequence, single-blind, placebo-controlled, three-period crossover study, 37 adults (BMI 25-34.9 kg/m²) received a single dose of a placebo, 150 mg TRPTI™, or 300 mg TRPTI™ following an overnight fast. Blood samples were collected over 8 hours, with standardised meals provided at 15 minutes and 4 hours post dose. Time-course responses of GLP-1, GIP, DPP-4, insulin, glucose, and glucagon were analysed. Results: Baseline adjusted GLP-1 and GIP AUC analyses demonstrated significant treatment effects across multiple pre-specified meal-related periods. The 300 mg TRPTI™ dose produced the greatest incretin responses and was significantly greater than placebo during selected pre-specified post-dosing and post-prandial periods, with elevations detectable within 15 minutes of ingestion. At key timepoints, GLP-1 concentrations were significantly higher (approximately 20-25%) than placebo. Similar significant increases were observed for GIP. Significant concentration changes in circulating DPP-4 were observed at later time points, indicating a potential association between TRPTI™ supplementation and serum DPP-4 modulation. Both TRPTI™ doses showed acute tolerability with safety biomarkers remaining within normal ranges. A statistically significant reduction in meal consumption was observed in both TRPTI™ groups. Conclusions: A single 300 mg dose of TRPTI™ enhances post-meal GLP-1 and GIP responses and demonstrates rapid engagement of GLP-1, GIP and DPP-4, supporting further investigation of its role in nutritional strategies targeting metabolic health. Clinical trial registration: https://clinicaltrials.gov/study/NCT06840080, identifier NCT06840080.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.